FY2024 EPS Estimates for Ascendis Pharma A/S (NASDAQ:ASND) Decreased by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Investment analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued on Tuesday, October 1st. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will earn ($6.80) per share for the year, down from […]

Leave a Reply

Your email address will not be published.

Previous post Q4 2024 Earnings Forecast for Carnival Co. & plc Issued By William Blair (NYSE:CCL)
Next post National Bank Financial Equities Analysts Raise Earnings Estimates for Cineplex Inc. (TSE:CGX)